DNA vs. NWBO

Last updated Apr 1, 2026

Compare and contrast key facts about Ginkgo Bioworks Holdings, Inc. (DNA) and Northwest Biotherapeutics, Inc. (NWBO).

Performance

DNA vs. NWBO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Northwest Biotherapeutics, Inc. (NWBO). The values are adjusted to include any dividend payments, if applicable.

DNA vs. NWBO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DNA Ginkgo Bioworks Holdings, Inc.	-26.23%	-15.38%	-85.47%	0.00%	-79.66%	-17.89%
NWBO Northwest Biotherapeutics, Inc.	-9.73%	-16.74%	-60.81%	-10.64%	12.07%	-50.70%

Fundamentals

Market Cap DNA : $339.96M NWBO : $308.11M
EPS DNA : -$5.65 NWBO : -$0.06
PS Ratio DNA : 1.99 NWBO : 322.89
Total Revenue (TTM) DNA : $170.16M NWBO : $937.00K
Gross Profit (TTM) DNA : $138.63M NWBO : $737.00K
EBITDA (TTM) DNA : -$215.86M NWBO : -$79.62M

Returns By Period

In the year-to-date period, DNA achieves a -26.23% return, which is significantly lower than NWBO's -9.73% return.

DNA

• 1D: 11.86%
• 1M: -9.19%
• YTD: -26.23%
• 6M: -57.96%
• 1Y: 7.54%
• 3Y*: -51.34%
• 5Y*: —
• 10Y*: —

NWBO

• 1D: 4.56%
• 1M: -8.59%
• YTD: -9.73%
• 6M: -14.03%
• 1Y: -9.59%
• 3Y*: -30.87%
• 5Y*: -31.76%
• 10Y*: -18.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DNA vs. NWBO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA

DNA Risk / Return Rank: 46
DNA Sharpe Ratio Rank: 45
DNA Sortino Ratio Rank: 53
DNA Omega Ratio Rank: 51
DNA Calmar Ratio Rank: 42
DNA Martin Ratio Rank: 42

NWBO

NWBO Risk / Return Rank: 40
NWBO Sharpe Ratio Rank: 36
NWBO Sortino Ratio Rank: 46
NWBO Omega Ratio Rank: 46
NWBO Calmar Ratio Rank: 34
NWBO Martin Ratio Rank: 37

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNA vs. NWBO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Northwest Biotherapeutics, Inc. (NWBO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DNA	NWBO	Difference
Sharpe ratio Return per unit of total volatility	0.08	-0.10	+0.17
Sortino ratio Return per unit of downside risk	0.86	0.63	+0.23
Omega ratio Gain probability vs. loss probability	1.10	1.09	+0.02
Calmar ratio Return relative to maximum drawdown	0.00	-0.22	+0.22
Martin ratio Return relative to average drawdown	0.01	-0.29	+0.29
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DNA vs. NWBO - Sharpe Ratio Comparison

The current DNA Sharpe Ratio is 0.08, which is higher than the NWBO Sharpe Ratio of -0.10. The chart below compares the historical Sharpe Ratios of DNA and NWBO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DNA	NWBO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.08	-0.10	+0.17
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.39	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.19	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.59	-0.17	-0.42

Correlation

The correlation between DNA and NWBO is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DNA vs. NWBO - Dividend Comparison

Neither DNA nor NWBO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DNA vs. NWBO - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, roughly equal to the maximum NWBO drawdown of -99.99%. Use the drawdown chart below to compare losses from any high point for DNA and NWBO.

Drawdown Indicators

	DNA	NWBO	Difference
Max Drawdown Largest peak-to-trough decline	-99.10%	-99.99%	+0.89%
Max Drawdown (1Y) Largest decline over 1 year	-66.05%	-54.89%	-11.16%
Max Drawdown (5Y) Largest decline over 5 years	—	-90.49%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-91.93%	—
Current Drawdown Current decline from peak	-98.97%	-99.98%	+1.01%
Average Drawdown Average peak-to-trough decline	-78.98%	-97.14%	+18.16%
Ulcer Index Depth and duration of drawdowns from previous peaks	32.41%	41.40%	-8.99%

Volatility

DNA vs. NWBO - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 28.02% compared to Northwest Biotherapeutics, Inc. (NWBO) at 15.46%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than NWBO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DNA	NWBO	Difference
Volatility (1M) Calculated over the trailing 1-month period	28.02%	15.46%	+12.56%
Volatility (6M) Calculated over the trailing 6-month period	73.00%	50.02%	+22.98%
Volatility (1Y) Calculated over the trailing 1-year period	100.38%	98.47%	+1.91%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	96.65%	82.30%	+14.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.65%	93.58%	+3.07%

Financials